Alexis Talbot

Hybrid ssDNA repair templates enable high yield genome engineering in primary cells for disease modeling and cell therapy manufacturing

Jonathan H. Esensten, A. Marson, Theodore L. Roth, 2021, bioRxiv.

NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia

J. Brumbaugh, K. Hochedlinger, O. Abdel-Wahab, 2022, Nature Immunology.

High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails

Jonathan H. Esensten, A. Marson, Eric Shifrut, 2022, Nature Biotechnology.

Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies

Chun Jimmie Ye, Kole T. Roybal, Daniel B. Goodman, 2022, Science Translational Medicine.

An evolved AAV variant enables efficient genetic engineering of murine T cells

Harold Pimentel, A. Asokan, Z. Steinhart, 2023, Cell.

Overcoming proteasome inhibitor resistance in the immunotherapy era.

Alexis Talbot, A. Wiita, B. Patiño-Escobar, 2023, Trends in pharmacological sciences.

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival

M. Amiot, C. Touzeau, Alexis Talbot, 2023, Frontiers in oncology.

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance

S. Vandenberg, R. Mullins, Scott VandenBerg, 2022, Nature Communications.